b-gc

BGC20-761 是一种选择性的5-HT6和多巴胺受体 (dopamine receptor) 拮抗剂，对人 5-HT6，5-HT2A，D2 受体的Ki 值分别为 20，69，和 140 nM。BGC20-761 可增强长期记忆。BGC20-761 具有作为抗精神病药物的潜在效用。

BGC-20-1531 (PGN 1531) free base 是选择性的、有效的前列腺素 EP4受体拮抗剂 (pKB: 7.6)，表现出偏头痛的研究潜力。

BGC-638, an analogue of BGC-945, is a thymidylate synthase inhibitor specifically transported into α-folate receptor (α-FR)–overexpressing tumors.

BGC201531 (AP-1531) 是一种 EP4 拮抗剂，用于治疗急性偏头痛。

BGC-20-1531 hydrochloride(1186532-61-5 free base) (GTPL3380 hydrochloride) 是一种 EP4 拮抗剂，用于治疗急性偏头痛。

Sertindole (Lu 23-174) 是一种非典型抗精神病药，可与多巴胺 D2 受体和血清素受体亚型 5-HT1D、5-HT2A 和 5-HT2C 结合，Kd 值分别为 2.7、20、0.14 和 6 nM。

(R)-Plevitrexed is a less active enantiomer of Plevitrexed. Plevitrexed is an orally active and potent inhibitor of thymidylate synthase (TS).

Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is an orally active and effective thymidylate synthase (TS) inhibitor (Ki: 0.44 nM). Plevitrexed is used for gastric cancer in clinical.

(Rac)-Plevitrexed is a racemate of Plevitrexed. Plevitrexed is an orally active and potent inhibitor of thymidylate synthase (TS).

ONX 0801 (BGC 945) trisodium is a targeted thymidylate synthase (TS) inhibitor specifically designed to act against tumors overexpressing the α-folate receptor.

Capsaicin ((E)-Capsaicin) 属于天然产物，提取自辣椒，是一种 TRPV1 激动剂 (EC50=0.29 μM)。Capsaicin 具有抗肿瘤、抗炎、抗氧化、神经保护等活性。

Vadimezan (DMXAA) 是一种血管破坏剂，一种鼠 STING 激动剂，也是一种细胞因子如 I 型 IFN 的诱导剂。Vadimezan 具有抗肿瘤活性，可以诱导肿瘤中的血流快速停止，但不影响正常组织中的血流。

Ursolic acid (Prunol) 属于天然产物，是一种五环三萜羧酸，提取自毛喉杜鹃。Ursolic acid 具有抗肿瘤、抗炎、抗菌、降血糖等活性。

Methotrexate (WR19039) 是一种叶酸类似物，一种二氢叶酸还原酶 DHFR 的抑制剂。Methotrexate 具有抗代谢、抗肿瘤和免疫抑制等活性，常用于类风湿关节炎和多种肿瘤的研究。

Sodium dichloroacetate (DCA) 是一种肿瘤细胞线粒体中的代谢调节剂，一种丙酮酸脱氢酶激酶 (PDK) 抑制剂。Sodium dichloroacetate 具有抗肿瘤活性，可以降低肿瘤微环境中的乳酸，增加活性氧的产生并促进肿瘤细胞凋亡。

Tanespimycin (KOS 953) 是一种 Hsp90 抑制剂，可选择性抑制 BT474 肿瘤细胞 Hsp90，IC50为 5 nM。它消耗细胞内 STK38 NDR1，并降低 STK38 激酶活性，还能下调stk38基因表达。

BGC0222 是一种新型的 Irinotecan 原药。作为 PEG-cRGD 偶联的 Irinotecan 衍生物，BGC0222 能够缓慢、稳定地释放 Irinotecan。它与 αVβ3 靶点结合，IC50 为 4.25 μM，对 αVβ5 的 IC50 为 58.7 μM。BGC0222 能诱导血管新生，并在多种肿瘤中显示出良好的抗肿瘤活性。

BGC4是一种基于联苯的金 (III) 复合物，能够抑制人类重组硫氧还蛋白还原酶 (TrxR)，其IC50为10.7 μM。它对MDA-MB-231细胞具有细胞毒性，IC50为5.4 μM，并能诱导细胞凋亡 (apoptosis)。在小鼠模型中，BGC4显示出抗肿瘤活性。

Combretastatin A-1 是一种有效的微管抑制剂，具有抗肿瘤和抗血管活性，通过微管蛋白解聚介导的 AKT 失活抑制 Wnt β-catenin 通路发挥作用，可用于研究肝癌。

GC-072是一种效力强大的4-oxoquinolizine类抗生素，具备选择性抑制细菌拓扑异构酶的能力。GC-072能够在体外对B. pseudomallei的敏感和耐药菌株展示效果，也能抑制Burkholderia mallei、Bacillus anthracis、Yersinia pestis和Francisella tularensis等危险病原体。在模拟小鼠类鼻疽感染的模型中，口服GC-072表现出剂量依赖性的生存优势，显示出其作为类鼻疽口服一线治疗方案的潜力。

Aflatoxin B2-13C17(AFB2-13C17) is intended for use as an internal standard for the quantification of AFB2by GC- or LC-MS. AFB2is a mycotoxin that has been found inA. terricola.1It induces hepatic autophagy and apoptosis in broiler chickens when administered at doses of 0.2, 0.4, and 0.8 mg kg.2AFB2(0.5 and 1 mg animal) also induces parenchymal cell hyperplasia in rats.3 1.Moubasher, A.H., el-Kady, I.A., and Shoriet, A.Toxigenic Aspergilli isolated from different sources in EgyptAnn. Nutr. Aliment.31(4-6)607-615(1977) 2.Chen, B., Li, D., Li, M., et al.Induction of mitochondria-mediated apoptosis and PI3K Akt mTOR-mediated autophagy by aflatoxin B2 in hepatocytes of broilersOncotarget7(51)84989-84998(2016) 3.Wogan, G.N., Edwards, G.S., and Newberne, P.M.Structure-activity relationships in toxicity and carcinogenicity of aflatoxins and analogsCancer Res.31(12)1936-1942(1971)

Flumequine-13C3is intended for use as an internal standard for the quantification of flumequine by GC- or LC-MS. Flumequine is a fluoroquinolone antibiotic.1It is active againstS. aureus, S. pyogenes, B. subtilis, E. coli, P. aeruginosa, S. faecalis, andK. pneumoniae(MICs = 1-100 μg ml). Flumequine is also active against field isolates of B. hyodysenteriae (MICs = 6.25-200 μg ml).2It inhibits DNA gyrase, disrupting supercoiling of bacterial DNA to block transcription and replication.3In vivo, flumequine (50 mg kg) increases survival in rat models ofP. vulgaris-induced urinary tract infection andP. mirabilis-induced prostatitis.1Formulations containing flumequine have been used in the treatment of urinary tract infections in veterinary medicine. 1.Rohlfing, S.R., Gerster, J.R., and Kvam, D.C.Bioevaluation of the antibacterial flumequine for urinary tract useAntimicrob. Agents Chemother.10(1)20-24(1976) 2.Aller-Morán, L.M., Martínez-Lobo, F.J., Rubio, P., et al.Evaluation of the in vitro activity of flumequine against field isolates of Brachyspira hyodysenteriaeRes. Vet. Sci.10351-53(2015) 3.Smith, J.T.The mode of action of 4-quinolones and possible mechanisms of resistanceJ. Antimicrob. Chemother.18 (Suppl. D)21-29(1986)

Rasagiline-13C3is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo(ED50= 0.1 mg kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease. 1.Youdim, M.B.H., Gross, A., and Finberg, J.P.Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBrit. J. Pharmacol.132(2)500-506(2001) 2.Youdim, M.B.H., and Weinstock, M.Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]Cell. Mol. Neurobiol.21(6)555-573(2001) 3.Kang, S.S., Ahn, E.H., Zhang, Z., et al.α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's diseaseEMBO J.37(12)e98878(2018)

Zanamivir-13C,15N2is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza. 1.Elliott, M.Zanamivir: From drug design to the clinicPhilos. Trans. R. Soc. Lond. B Biol Sci.356(1416)1885-1893(2001)